Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Federal Trade Commission
Chinese Patent Office
Citi
Dow
Chubb
Merck
Queensland Health
Daiichi Sankyo

Generated: August 15, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,504,640

« Back to Dashboard

Title:Modified release formulations of a bupropion salt
Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Inventor(s): Oberegger; Werner (Mississauga, CA), Zhou; Fang (Centreville, VA), Maes; Paul (Toronto, CA), Turchetta; Stefano (Rome, IT), Jackson; Graham (County Kildare, IE), Massardo; Pietro (Rome, IT), Saleh; Mohammad Ashty (Oakville, CA)
Assignee: Valeant Pharmaceuticals Luxembourg S. .R.L. (Luxembourg, LU)
Filing Date:Sep 02, 2014
Application Number:14/474,580
Claims:1. A modified release osmotic dosage form comprising bupropion hydrobromide present in a therapeutically effective amount, wherein said dosage form releases the bupropion hydrobromide by dispensing the bupropion hydrobromide from a core via at least one passageway in a membrane by pressure created in the core by osmosis and/or by the expansion of a swellable material which forces the bupropion hydrobromide to be dispensed from the core of the dosage form, and wherein the core is surrounded by a subcoat containing an osmagent.

2. The modified release osmotic dosage form according to claim 1, wherein said dosage form exhibits an in-vitro release rate such that after 2 hours from 0 to 20% by weight of the bupropion hydrobromide is released, after 4 hours from 15% to 45% by weight of the bupropion hydrobromide is released, after 8 hours, from 40% to 90% by weight of the bupropion hydrobromide is released, and after 16 hours, more than 80% by weight of the bupropion hydrobromide is released.

3. The modified release osmotic dosage form according to claim 1, wherein said osmagent is selected from the group consisting of sodium chloride, calcium chloride, calcium lactate, sodium sulfate, lactose, glucose, sucrose, mannitol, urea, and mixtures thereof.

4. A modified release osmotic dosage, wherein a core comprising bupropion hydrobromide is surrounded by a subcoat containing an osmagent, said core and subcoat surrounded by a semipermeable membrane which permits entry of an aqueous liquid into the core and delivery of the bupropion hydrobromide from the core to the exterior of the dosage form through at least one passageway or by a combination of osmosis and diffusion such that the dosage form exhibits an in-vitro release rate such that after 2 hours no more than 40% is released, after 4 hours 40-75% is released, and after 8 hours at least 75% is released and after 16 hours at least 85% is released.

5. The modified release osmotic dosage form according to claim 1, wherein said core comprising bupropion hydrobromide and said subcoat surrounding the core are surrounded by a semipermeable membrane.

6. The modified release osmotic dosage form according to claim 3, wherein said subcoat further comprises a hydrophilic polymer.

7. The modified release osmotic dosage form according to claim 6, wherein said hydrophilic polymer is selected from the group consisting of polyvinyl pyrrolidone, hydroxyethyl cellulose, hydroxypropyl cellulose, polymethacrylate, ethyl cellulose and mixtures thereof.

8. The modified release osmotic dosage form according to claim 6, wherein said hydrophilic polymer comprises a low molecular weight hydroxypropyl cellulose.

9. The modified release osmotic dosage form according to claim 4, wherein said subcoat further comprises a hydrophilic polymer.

10. The modified release osmotic dosage form according to claim 9, wherein said hydrophilic polymer is selected from the group consisting of polyvinyl pyrrolidone, hydroxyethyl cellulose, hydroxypropyl cellulose, polymethacrylate, ethyl cellulose and mixtures thereof.

11. The modified release osmotic dosage form according to claim 9, wherein said hydrophilic polymer comprises a low molecular weight hydroxypropyl cellulose.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
UBS
Medtronic
Cipla
AstraZeneca
Queensland Health
Harvard Business School
Merck
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.